RE:Deals struck with Big Pharma companies
Theralase Technologies It will take at least a couple of years for Theralase Technologies Inc.’s cancer treatment technology to become regulated (and at least a year before we know how well it works on humans), but the healthcare tech they have under development is worth talking about. The Ontario company has been working on photo-sensitive anti-cancer drugs (or “Photo Dynamic Compounds”) that, when injected at the site of a tumour, can kill cancer cells when activated by light. If approved for use, the company claims its methods would be more effective at killing cancer cells than existing drugs. Theralase has been conducting its research in Toronto at Princess Margaret Hospital, and says its current focus is on finding a better method for treating bladder cancer. Human clinical trials won’t start until at least January 2015, but the company has already attracted the interest of Big Pharma companies such as Bayer and GlaxoSmithKline. Both have already struck multi-million dollar commercialization and royalties deals with Theralase